The Current State of Drug Pricing Transparency


As more states adopt drug pricing transparency laws to help lower the cost of prescription drugs, pharmaceutical manufacturers, especially those about to launch their first therapy, must understand the changing legal landscape and what it means for their business now and in the future.

In this informative discussion, Rupal Patel, Director of Advisory Services, and John Whitridge, Senior Advisory Services Consultant discuss the current state of drug pricing transparency laws, including:

  • What manufacturers can do now to comply with existing laws
  • How pre-commercial companies can gain a competitive advantage at launch
  • Lessons learned from over 50 customer implementations



    Rupal Patel    John Whitridge

    Please fill out the form to listen to the discussion.

    To download our datasheet detailing solutions to reduce compliance risk around state price transparency, click here

    adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article